Welcome to our dedicated page for Mountain Vy Md news (Ticker: MVMDF), a resource for investors and traders seeking the latest updates and insights on Mountain Vy Md stock.
Mountain Valley MD Holdings Inc. (MVMDF) features regularly in corporate news for its progress across three stated business lines: nutraceuticals using its patented Quicksome™ oral formulation technology, husbandry animal and aquatic applications based on its Quicksol™ solubility platform, and agricultural initiatives centered on the licensed Agrarius™ plant signaling technology. Company updates often detail commercialization milestones, licensing agreements, and field trial results.
News releases describe how Mountain Valley MD works with a U.S.-based GMP manufacturing partner to produce Quicksome™-powered sublingual nutraceutical products for licensees and for its proprietary “Mountains Of…” brand. Coverage includes product launches and formulation work for categories such as sleep, energy, immunity, stress and anxiety support, and other wellness-focused applications.
In agriculture, the company’s news flow highlights its exclusive license to sell Agrarius™ across North America, Mexico, Central America, South America, and the Caribbean, along with extensive crop trials and a Performance Guarantee Program under which clients pay only if defined yield or plant health thresholds are met. Updates frequently summarize trial outcomes in crops like citrus, corn, sugarcane, soybeans, potatoes, cotton, and pasture grass, as well as regulatory and registration progress in various jurisdictions.
For husbandry animals and aquatic species, Mountain Valley MD reports on the development and licensing of Soluvec™ 1%, a Quicksol™-based ivermectin formulation, including agreements with partners such as a Bangladesh licensee. Investors and observers can use this news page to follow the company’s reported commercialization steps, partnership developments, and technology validation efforts over time.
Mountain Valley MD Holdings Inc. (CSE: MVMD, OTCQX: MVMDF) provided a business update highlighting its advanced technologies designed to enhance drug efficacy, administration, and safety. Key technologies include Quicksome™ for cold chain management of vaccines and Quicksol™ for solubilizing anti-parasitic drugs. The company is also expanding its focus into needleless insulin delivery and tackling tuberculosis with its Selactosol™ product. Ongoing collaborations aim to optimize applications across various health sectors, with pre-clinical studies expected to commence later in 2022.
Mountain Valley MD Holdings Inc. (MVMD) appointed Dr. Elizabeth Norton to an advisory role to enhance its Quicksome™ vaccine and cold chain projects. Dr. Norton, an experienced immunologist, has a solid background in vaccines and public health and currently serves as an Associate Professor at Tulane University. She takes over from Dr. John D. Clements, who is retiring but will continue to assist on an ad-hoc basis. MVMD aims to improve global vaccine access and effectiveness through its innovative Quicksome™ technology.
Mountain Valley MD Holdings announced the adoption of a restricted share unit plan (RSU Plan) and granted 875,000 RSUs and 2,525,000 stock options. The RSUs vest based on performance milestones to be achieved by December 31, 2022. The options, exercisable at $0.22 per share, have a vesting schedule over one year. MVMD aims to align employee incentives with long-term shareholder value while preserving cash expenditures, promoting its patented Quicksome™ and Quicksol™ technologies for effective drug and vaccine delivery.
Mountain Valley MD Holdings Inc. (MVMD) announced a Product Development and Commercial Licensing Agreement with Red White & Bloom Brands Inc. (RWB). This collaboration will leverage MVMD's Quicksome™ technology to create innovative cannabis products. RWB gains an exclusive five-year license to manufacture and distribute these products in Florida, Michigan, and California, alongside payment of product fees and sales royalties. The initial product will be a THC-based sleep formulation aimed at the medical sleep market. MVMD is also finalizing a patent to protect its cannabinoid solubilization techniques.
Mountain Valley MD Holdings Inc. (MVMD) provided a business update on September 29, 2021, detailing advancements in oncology research, husbandry animal trials, and the development of its ivermectin formulations.
Key initiatives include expanded oncology trials for triple-negative breast cancer and melanoma, successful husbandry trials in Bangladesh with Ivectosol™ 1%, and the introduction of Ivectol™ for generic ivermectin production. The company plans commercialization in 2022 pending approvals. Shareholders approved board re-elections and an independent auditor but rejected a share consolidation proposal.
Mountain Valley MD Holdings Inc. has announced a letter of intent with Red White & Bloom Brands Inc. to establish a licensing agreement focused on cannabis product development. The agreement aims to leverage Mountain Valley's Quicksome™ technology for the formulation of cannabis products in Florida, Michigan, and California. Anticipated completion of the product development agreement is by October 2021, with provisions for research fees and royalties. This partnership is expected to validate Mountain Valley’s formulation technology in the expanding U.S. cannabis market.
Mountain Valley MD Holdings Inc. (MVMD) will hold its annual general and special meeting on September 21, 2021, at 11:30 a.m. ET. Shareholders will vote on key issues including a proposed continuance to Ontario and a share consolidation of up to ten existing shares for one new share. While the continuance aims to improve operational efficiency, it is not expected to affect the company’s business or assets. Shareholder approval is also sought for amending the stock option plan to comply with regulations of other potential stock exchanges in Canada.
Mountain Valley MD Holdings Inc. is set to upgrade its trading status from the OTCQB Venture Market to the OTCQX Best Market, effective August 27, 2021, under the symbol MVMDF. This transition reflects MVMD's compliance with elevated financial standards and corporate governance practices. The move is expected to enhance visibility among U.S. investors and improve share liquidity. The company is also reviewing options for further listings on the TSX Venture Exchange or NEO Exchange, aiming for greater exposure and institutional investor interest.
Mountain Valley MD Holdings Inc. (MVMDF) announces the appointment of Dr. Azhar Rana as Chief Medical Officer. Dr. Rana brings nearly two decades of experience in clinical development and medical affairs, including leadership roles at Bristol Myers-Squibb and AstraZeneca. His expertise will support MVMD's strategy in advancing its patented Quicksome™ and Quicksol™ technologies, aimed at enhancing drug delivery systems. The company granted Dr. Rana 1,000,000 stock options at $0.365 per share, vesting over five years. This strategic appointment is expected to propel MVMD's growth in health and wellness applications.
Mountain Valley MD Holdings Inc. (CSE: MVMD) announced the appointment of Gokul Kannan and Mark Gelnaw as advisors, aimed at enhancing its oncology research and technological applications. Kannan, a bioengineering expert, has significant research credentials, while Gelnaw brings over 35 years of financial and strategic experience. The company is also progressing a listing application for the TSX Venture Exchange or NEO Exchange, which could improve its market exposure. Additionally, the Company granted 3,725,000 stock options at an exercise price of $0.27, indicating strategic growth plans.
FAQ
What is the current stock price of Mountain Vy Md (MVMDF)?
What is the market cap of Mountain Vy Md (MVMDF)?
